FDA approves Hetlioz: first treatment for non-24 hour sleep-wake disorder in …

FDA approves Hetlioz: first treatment for non-24 hour sleep-wake disorder in …

The U.S. Food and Drug Administration today approved Hetlioz (tasimelteon), a melatonin receptor agonist, to treat non-24- hour sleep-wake disorder (“non-24”) in totally blind individuals. Non-24 is a chronic circadian rhythm (body clock) disorder in

10
Like
Save

Comments

Write a comment

*